Why the study?
Does carvedilol induce biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility?
Does carvedilol induce biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility?
Carvedilol promotes cardiac inotropy through a novel β1AR-NOS3 signalling pathway, suggesting a potential therapeutic target for heart failure with reduced ejection fraction.
Hypothesis-generating for carvedilol's biased β1AR-NOS3-cGMP pathway in HFrEF; leaves open translation to human therapy.
These observations present a novel β1AR-NOS3 signalling pathway to promote cardiac inotropy in the heart, indicating that this signalling paradigm may be targeted in therapy of heart diseases with reduced ejection fraction.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: